AlphaRET is a wholly owned subsidiary of Nova Eye Medical Limited, established to drive the commercial development of the 2RT® project. 2RT® is based on seminal laboratory investigations performed by world-renowned retinal expert Prof. John Marshall PhD, FRCPath, FMedDSci (Institute of Ophthalmology, University College London, UK) and is a proprietary minimally invasive nano-pulse ophthalmic laser therapy which, in the 2019 Phase 2 LEAD” clinical study, demonstrated efficacy in a subset of patients in the treatment of intermediate age-related macular degeneration (iAMD).

Current research suggests that 2RT® stimulates a natural immune response of the retina, which restores natural metabolite flow and rejuvenates the retinal pigment epithelium– without damage to the overlying neurosensory retina (specifically, no damage is caused to the photoreceptors) or the underlying Bruch’s membrane. Importantly, 2RT® offers the potential to intervene earlier in the disease process and thereby eliminate or delay the risk of vision-threatening complications associated with AMD – offering a breakthrough approach to the management of AMD patients.

Jobling, A.I., et al., Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage. FASEB J, 2015. 29,696710.

…if we can slow down the basal rate of Bruch’s membrane aging and restore function to what it was when the patient was in their teens, we should be able to significantly delay AMD onset.”

2RT Approved Indications of Use

The treatment of Clinically Significant Macular Edema (CSME); and
In patients with early Age-related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function.

US 510(k):
The treatment of Clinically Significant Macular Edema (CSME).

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More